Serum sPD1 and sPDL1 as Biomarkers for Evaluating the Immune State of Lung Adenocarcinoma Patients

Table 1

Clinical information for patients.

Clinical characteristics	Cases	Percentage (%)
Ages
≥60	21	70%
<60	9	30%
Gender
Male	17	56.67%
Female	13	43.33%
TNM stage
I+II	14	46.57%
III+IV	16	53.33%